Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Analysis of Antibody Neutralization Efficiency, Seroprevalence and Long Term Immunity in SARS-CoV-2-Positive Individuals Identified in a Surveillance Survey of At-Risk Individuals

EF 2020-21

Résumé
As the pandemic of Sars-CoV 2 continues to spread, it's associated disease (COVID-19) has resulted in hundreds of thousands of deaths and deep socioeconomical impact. The immunity to this new virus is still poorly understood. To answer those questions, 500 convalescent individuals and 500 healthy primary school teachers, daycare personnel, frontline medical workers in hospitals, and elderly people living in retirement homes are being recruited. We will monitor them every two weeks for the virus and monthly for antibodies. Using our establishes serological assay and high-throughput robotic platform, we will monitor all antibody isotypes and subtypes against all immunogenic targets of the virus (full trimeric spike, receptor binding domain and nucleoprotein). We will also monitor the Neutralization efficiency and the presence of ACE2 autoantibodies (As they were recently shown to be present and correlated with severe COVID-19). The information learned from my project will enable early detection of infection and thereby reduce the spread of the virus and we will acquire a better sense of the numbers of asymptomatic and symptomatic individuals exposed to COVID-19. Critical information about antibody-mediated immunity and how long the immunity will last will be shared with the scientific community and local/regional/national health authorities. This new knowledge will help vaccine developers make the right decisions about how to create their vaccines while allowing public health officials to make more informed decisions.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
449703
Name
Galipeau Yannick
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Analysis of Antibody Neutralization Efficiency, Seroprevalence and Long Term Immunity in SARS-CoV-2-Positive Individuals Identified in a Surveillance Survey of At-Risk Individuals
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antibody Mediated Immunity; Autoantibodies; Covid-19; Cross-Reactivity; Long Term Immunity; Longitudinal Study; Sars-Cov-2; Seasonal Coronaviruses; Serology; Viral Immunology
Abstract
As the pandemic of Sars-CoV 2 continues to spread, it's associated disease (COVID-19) has resulted in hundreds of thousands of deaths and deep socioeconomical impact. The immunity to this new virus is still poorly understood. To answer those questions, 500 convalescent individuals and 500 healthy primary school teachers, daycare personnel, frontline medical workers in hospitals, and elderly people living in retirement homes are being recruited. We will monitor them every two weeks for the virus and monthly for antibodies. Using our establishes serological assay and high-throughput robotic platform, we will monitor all antibody isotypes and subtypes against all immunogenic targets of the virus (full trimeric spike, receptor binding domain and nucleoprotein). We will also monitor the Neutralization efficiency and the presence of ACE2 autoantibodies (As they were recently shown to be present and correlated with severe COVID-19). The information learned from my project will enable early detection of infection and thereby reduce the spread of the virus and we will acquire a better sense of the numbers of asymptomatic and symptomatic individuals exposed to COVID-19. Critical information about antibody-mediated immunity and how long the immunity will last will be shared with the scientific community and local/regional/national health authorities. This new knowledge will help vaccine developers make the right decisions about how to create their vaccines while allowing public health officials to make more informed decisions.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Galipeau, Yannick
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~